Loading…
Loading…
New patent broadens protection around systems integrating real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer pain
THE WOODLANDS, TX, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on July 15, 2026 (the “July 2026 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding July 2026 Warrants to purchase an aggregate of 857,462 shares of the Company's common stock at the exercise price of $5.75. The resale of the shares of common stock issuable upon exercise of the July 2026 Warrants has been registered pursuant to an effective registration statement on Form S-3 (File No. 333-297760). The gross proceeds from the exercise of the warrants are expected to be approximately $4.9 million, prior to deducting financial advisory fees and estimated offering expenses.
Final histology and laboratory analyses support the study's safety and performance objectives THE WOODLANDS, TX, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of its Good Laboratory Practice (GLP) pre-clinical study, a significant regulatory milestone supporting the Company's submission to the U.S. Food and Drug Administration (FDA). The study was conducted in accordance with FDA Good Laboratory Practice standards and evaluated the safety, functionality and performance of the Autonomix platform across multiple clinically relevant anatomical targets in porcine models.
Recognition honors one of the medical technology industry's most influential innovators, whose career has helped shape modern cardiovascular care
Autonomix Medical Inc. (NASDAQ:AMIX) shares are skyrocketing Tuesday afternoon after securing U.S. Patent No. 12,433,670.
Patent expands protection for technology designed to sense, map and selectively target nerves associated with tumors and cancer-related pain
Data demonstrate the ability to detect, localize and confirm changes in renal neural activity, supporting continued development of physiology-guided renal denervation THE WOODLANDS, TX, July 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced positive results from a preclinical study demonstrating the ability of its proprietary neural sensing platform to detect, localize and confirm changes in renal neural activity.
Data demonstrate the ability to detect, localize and confirm changes in renal neural activity, supporting continued development of physiology-guided renal denervation